We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Opioid Addiction Treatment Co. Nabs $110M For New Product

Law360, New York (January 11, 2018, 6:51 PM EST) -- Braeburn Pharmaceuticals Inc. on Thursday said investors contributed $110 million to a recent funding round as the biotechnology firm targets regulatory approvals and commercialization of the company's latest opioid addiction treatment....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.